Differential Use of Functional Domains by Coiled-coil Coactivator in Its Synergistic Coactivator Function with β-Catenin or GRIP1*§

Catherine K. Yang‡, Jeong Hoon Kim§1, Hongwei Li§, and Michael R. Stallcup§2

From the Departments of ‡Biochemistry and Molecular Biology and of §Pathology, University of Southern California, Los Angeles, California 90089

β-Catenin, a pivotal component of the Wnt-signaling pathway, binds to and serves as a transcriptional coactivator for the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of transcriptional activator proteins and for the androgen receptor (AR), a nuclear receptor. Three components of the p160 nuclear receptor coactivator complex, including CARM1, p300/CBP, and GRIP1 (one of the p160 coactivators), bind to and cooperate with β-catenin to enhance transcriptional activation by TCF/LEF and AR. Here we report that another component of the p160 nuclear receptor coactivator complex, the coiled-coil coactivator (CoCoA), directly binds to and cooperates synergistically with β-catenin as a coactivator for AR and TCF/LEF. CoCoA uses different domains to bind GRIP1 and β-catenin, and it uses different domains to transmit the activating signal to the transcription machinery, depending on whether it is bound to GRIP1 or β-catenin. CoCoA associated specifically with the promoters of transiently transfected and endogenous target genes of TCF/LEF, and reduction of the endogenous CoCoA level decreased the ability of TCF/LEF and β-catenin to activate transcription of transient and endogenous target genes. Thus, CoCoA uses different combinations of functional domains to serve as a physiologically relevant component of the Wnt/β-catenin signaling pathway and the androgen signaling pathway.

The Wnt/β-catenin-signaling cascade plays important roles in developmental processes. Inappropriate activation of this pathway is associated with a variety of cancers such as colorectal cancer and hepatocellular carcinoma (1, 2). Activation of this pathway by extracellular Wnt ligands results in increased intracellular levels of β-catenin, which consists of N- and C-terminal activation domains flanking twelve armadillo repeats and serves as a coactivator for various DNA-binding transcription factors. In the absence of stimulation by Wnt ligand, β-catenin levels are maintained at a low level through a specific degradation mechanism. Phosphorylation of β-catenin by glycogen synthase kinase 3β targets β-catenin for ubiquitylation and degradation via ubiquitin-mediated proteasomal degradation (2, 3). Activation of the cell-surface Frizzled receptor by binding of the Wnt ligand activates a signaling pathway, which leads to inactivation of glycogen synthase kinase 3β by destabilizing its complex with axin and the adenosomatous polyposis coli tumor suppressor protein. The resulting reduced degradation of β-catenin leads to enhanced cellular levels of β-catenin, which allows its nuclear translocation and accumulation. In the nucleus β-catenin binds to and serves as a primary coactivator for the T-cell factor/lymphoid enhancer factor (TCF/LEF) proteins (4, 5). In so doing, β-catenin displaces the corepressors Groucho (6) and CbP (7) and thus converts the TCF/LEF complex from a transcriptional repressor to a transcriptional activator.

β-Catenin also serves as a coactivator for the androgen receptor (AR) (8, 9), which is a member of the nuclear receptor (NR) family of hormone-regulated transcriptional activator proteins. Binding of hormone to AR results in a conformational change that allows AR to associate with specific target genes, either by direct binding of specific enhancer elements or through protein-protein interactions with other DNA-bound transcription factors (10, 11). AR recruits a variety of coregulator proteins to the target gene promoter, and these coregulators mediate the activation or repression of transcription by modulation of chromatin conformation and recruitment and activation of RNA polymerase II and its associated transcription factors (11–13). The fact that more than 200 different putative coregulator proteins for NRs have been identified over the past decade§ indicates that the process of transcriptional regulation is extremely complex, involving distinct contributions from many different coregulator complexes. For example, the TRAP/DNIP/Mediator complex helps to recruit and activate RNA polymerase II, and Swi/Snf is an ATP-dependent chromatin-remodeling complex (12). The p160 coactivator complex also contributes to chromatin remodeling but by a different mechanism that involves acetylation and methylation of histones (12, 14, 15). The p160 complex is anchored to the hormone-activated, DNA-bound NR by one of the three p160 coactivator proteins, which include SRC-1, GRIP1/ThF2, and pCIP/ACTR/AIB1/RAC3/TRAM1. The p160 protein is thus a primary coactivator, which serves as a scaffold to recruit a variety of secondary coactivators (16). These include the protein arginine methyltransferase CARM1 (17), the protein acetyltransferases p300 and CBP (18–20), and the coiled-coil coactivator CoCoA (21), which contributes to transcriptional activation by an unknown mechanism.

The mechanism by which β-catenin contributes to transcriptional activation, after binding to AR or TCF/LEF, has recently begun to emerge. β-Catenin can bind to various components of the p160 nuclear receptor coactivator complex, including GRIP1 (9, 22), CARM1 (23), CoCoA-R, siRNA-resistant mutant of CoCoA.

3 The abbreviations used are: TCF/LEF, T-cell factor/lymphoid enhancer factor; AR, androgen receptor; NR, nuclear receptor; HA, hemagglutinin; CBP, CREB-binding protein; CoCoA, coiled-coil coactivator; DBD, DNA-binding domain; GST, glutathione S-transferase; siRNA, small interference RNA; RT, reverse transcription; MMTV, murine mammary tumor virus; CoCoA-R, siRNA-resistant mutant of CoCoA.

4 B. W. O’Malley and R. M. Evans, Nuclear Receptor Signaling Atlas, www.nursa.org/index.cfm.

* This work was supported in part by National Institutes of Health Grant DK43093 (to M. R. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article therefore must be hereby marked ”advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2.

1 Supported by a predoctoral fellowship from the University of Southern California/Norris Cancer Center Breast Cancer Research Training Program.

2 To whom correspondence should be addressed: Dept. of Pathology, HMR 301, University of Southern California, 2011 Zonal Ave., Los Angeles, CA 90089-9092. Tel.: 323-442-1289; Fax: 323-442-1224; E-mail: stallcup@usc.edu.

© 2006 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
Coactivator Synergy between β-Catenin and CoCoA

and p300/CREB (24–26), and β-catenin cooperates synergistically as a coactivator for AR and TCF/LEF with each of these NR coactivators. To further investigate the mechanism of β-catenin coactivator function and the collaboration between β-catenin and the p160 coactivator complex, we tested whether the recently identified coiled-coil coactivator CoCoA can bind to and cooperate with β-catenin. CoCoA is the product of the human calcocoI gene and functions as a secondary coactivator for NRs. That is, it does not bind directly to NRs or act by itself as a NR coactivator; instead, it is apparently recruited to the promoter through the functional PAS domain of p160 coactivators, and the coactivator activity of CoCoA depends on the co-expression of a p160 coactivator (21). Here we demonstrate that CoCoA can bind to β-catenin and act as a secondary coactivator for the AR and TCF/LEF pathways through that interaction. We also found that CoCoA uses different domains for binding to and activating transcription in cooperation with β-catenin versus p160 coactivators.

MATERIALS AND METHODS

Plasmids—The plasmids, pSG5.HA-β-catenin encoding chicken β-catenin with an N-terminal hemagglutinin (HA) epitope tag, pβ-catenin encoding Gal4 DNA-binding domain (DBD) fused to β-catenin, pS5.G5.HA-LEFI encoding HA-tagged LEF1, pS5.G5.HA-GRIP1, pGEX-4T1-β-catenin encoding glutathione S-transferase (GST) fused to β-catenin (for bacterial expression), and luciferase reporter gene plasmids MMTV-LUC (for AR), pGL3OT (for LEF1), and GK1-LUC (for Gal4) were previously described (22). PCR-amplified β-catenin cDNA fragments were inserted into Xhol and BgIII sites of pSG5.HA vector. pcDNA3.1-CoCoA/V5-His, pGEX-5X1,CoCoA, pS5.G5.HA-CoCoA, pS5.G5.HA-CoCoA-(1–149), pS5.G5.HA-CoCoA-(1–190), pS5.G5.HA-CoCoA-(1–500), pS5.G5.HA-CoCoA-(140–274), pS5.G5.HA-CoCoA-(150–500), pS5.G5.HA-CoCoA-(274–510), pS5.G5.HA-CoCoA-(150–691), pS5.G5.HA-CoCoA-(470–691), pS5.G5.HA-CoCoA-(501–691), pM.CoCoA-(1–500), pM.CoCoA-(150–691), and pM.GRIP1-(5–479) were described previously (21). pS5.G5.HA-CoCoA-R, encodes wild-type CoCoA but contains silent mutations in codons 29–31 to make it resistant to a CoCoA-specific small interfering RNA (siRNA); the QuikChange site-directed mutagenesis kit (Stratagene) was used to generate the mutations with primers 5′-CATCCCCCAAACCAAAAGTGCTGGTGCTACTACATTGGTGG-3′ (forward) and 5′-CAAAAGTGTAGTGACATCGTGTTGCTGTTGGGGATG-3′ (reverse) (mutations are shown in lowercase).

Cell Culture, Transfections.—CV-1, COS-7, and SW480 cells were maintained in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum and penicillin and streptomycin. For reporter gene assays, CV-1 cells were transiently transfected in 12-well plates and assayed for luciferase activity as described previously (21). Protein-Protein Interaction Assay—GST pull-down assays were performed as described previously (21) using extracts from COS-7 cells maintained as described previously (21). Protein-Protein Interaction Assays—GST pull-down assays were performed as described previously (21). COS-7 cells in 100-mm dishes were transfected with reporter gene and expression plasmids as described. 24 h after transfection, cells were treated with 20 mM LiCl to inhibit glycogen synthase kinase 3β and increase β-catenin levels, and soluble chromatin fractions were prepared 48 h post-transfection. Immunoprecipitation was performed using 2 μg of anti-LEF1 antibody C-19 (Santa Cruz Biotechnology) or anti-β-catenin antibody, or 8 μl of an equal mixture of two rabbit antisera against CoCoA (21). Chromatin immunoprecipitation assays were performed as described previously (21). Briefly, SW480 cells were cultured in 150-mm dishes and treated with 20 mM LiCl for 24 h. Immunoprecipitation was performed as in reporter co-immunoprecipitation assays, and PCR amplification of the precipitated DNA was performed with primers spanning the cyclin D1 promoter: −795 to −502, 5′-CAAGGACCGACTGTGCAG-3′ (forward) and 5′-ACACGTGTAAATTGCAGAATCTA-3′ (reverse); +128 to +486, 5′-CGGGGCGAGCAAGCAGGGA-3′ (forward) and 5′-GTGACTAGCAGAAAGCAGTTG-3′ (reverse); −3892 to −3649, 5′-GGTGTCCTCCCGCAGTCTTC-3′ (forward) and 5′-CCTCCGCCGAGTCCAGG-3′ (reverse). The amount of each immunoprecipitated DNA sample was titrated to determine the linear range for the PCR reactions, and the results shown were within the linear range.

RNA Interference and Rescue Assays—siRNA transfection into cultured mammalian cells was described previously (21). The following siRNA were used for transfection: Scramble1 and siCoCoA1 were described previously (21); Scramble2: 5′-GUCCUCGUAAUACACUACCTTC-3′ (sense) and 5′-GUUAGUUGUAAUGAGGGACTT-3′ (antisense); siCoCoA2: 5′-UGACCGUGACGUGAACAGTTT-3′ (sense) and 5′-CUUCAGCUCUGCAUCAGGUACTT-3′ (antisense); siβ-catenin: 5′-ACGCUGUAGUAGGACAGTT-3′ (sense) and 5′-CU-GUCCCUAUAAUACACCTT-3′ (antisense). COS-7 or CV-1 cells were transfected with siRNA duplex, reporter plasmid, and plasmids encoding the indicated proteins using Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions and assayed for luciferase reporter activity. For RT-PCR, total RNA of transfected cells were extracted using TRIzol reagent (Invitrogen), and analysis was performed using Access RT-PCR system (Promega). The following primers were used for RT-PCR: CoCoA, 5′-CACACCACTGTCCAGTTC-CAA-3′ (forward) and 5′-CTTGCAGCACTTTTCTACT-3′ (reverse); β-catenin, 5′-CTTTCGCTGCACTTTTCTACT-3′ (forward) and 5′-GGATCCTCAGTGGATCTGCG-3′ (reverse). siRNA rescue assays were performed by transfecting CV-1 cells with 40 pmol of siRNA using Lipofectamine 2000 according to the manufacturer’s instructions. 48 h after siRNA transfection, reporter gene and expression plasmids were transfected using Targitect F1 (Targeting Systems) for 24 h, and cell lysates were then assayed for luciferase activity.

To assess the effect of reducing endogenous CoCoA level on the expression of an endogenous target gene of LEF1 and β-catenin, SW480 cells in 6-well plates were transfected with siRNA duplex using Lipofectamine 2000 following the manufacturer’s instructions. Total RNA was extracted with TRizol reagent (Invitrogen), and the reverse transcriptase reaction was performed with iScript cDNA Synthesis Kit (Bio-Rad Laboratories). Quantitative real-time PCR reactions were performed with Brilliant SYBR Green QPCR Master Mix (Stratagene) with the Mx3000P system (Stratagene) using the following primers: CoCoA, 5′-GACCTCACATCCCCAAACCAACAAAGTGCTGGTGCTACTACATTGGTGG-3′ (forward) and 5′-CAAAAGTGTAGTGACATCGTGTTGCTGTTGGGGATG-3′ (reverse); Cyclin D1, 5′-GTGCTCGCGGGAATGCTGAAGG-3′ (forward) and 5′-TCGGGCGGATGGGTGGTGTCG-3′ (reverse); glyceraldehyde-3-phosphate dehydrogenase, 5′-TCTGTTGAAATCATTGTGGTGGTGTCG-3′ (forward) and 5′-GATTGATGGGGATTTCC-3′ (reverse). Following PCR, a melting curve was obtained to confirm the purity of the amplification product. Relative
expression levels of the target genes were obtained with the built-in software of the Mx3000P system, using the standard curve method, and were normalized to the expression level of glyceraldehyde-3-phosphate dehydrogenase.

RESULTS

CoCoA Binds to β-Catenin—Given that members of the p160 NR coactivator complex, including CARM1 (23), p300/CBP (24–26), and GRIP1 (9, 22), have been shown to associate with β-catenin, we tested whether another component of the p160 NR coactivator complex, CoCoA, can interact with β-catenin. To test for binding in vitro, HA-tagged CoCoA (Fig. 1A, lane 1) or β-catenin (lane 4) was expressed in COS-7 cells by transient transfection, and the COS-7 cell extracts were incubated with GST-β-catenin or GST-CoCoA, respectively. CoCoA effectively bound to GST-β-catenin (lane 3) but not to GST (lane 2). Conversely, β-catenin in COS-7 cell extracts bound to GST-CoCoA (lane 6) but not to GST (lane 5).

To test binding in vivo by co-immunoprecipitation, HA-tagged β-catenin and V5-tagged CoCoA were expressed in COS-7 cells (Fig. 1B, lanes 1–3). Anti-β-catenin antibody effectively precipitated CoCoA (lane 5), even in the absence of exogenously expressed β-catenin (lane 7). This was presumably due to the presence of endogenous β-catenin (middle panels); note that the total β-catenin level was the same regardless of whether the β-catenin expression vector was transfected or not (lanes 1–5, middle panels), indicating a high level of endogenous β-catenin expression. Normal IgG failed to bring down either CoCoA or β-catenin (lane 4). Co-immunoprecipitation of the two proteins was performed as in B, using anti-CoCoA antiserum for immunoprecipitation and anti-V5 antibody (lower panel) or anti-HA antibody (top panel) or anti-V5 antibody (bottom panel) for immunoblots.

Coactivator Synergy between β-Catenin and CoCoA

FIGURE 1. CoCoA interacts with β-catenin in vitro and in vivo. A, plasmids encoding HA-tagged CoCoA or β-catenin were transfected into COS-7 cells. Cell lysates were collected 48 h after transfection and incubated with glutathione-Sepharose beads containing GST (lanes 2 and 5), GST-β-catenin (lane 3), or GST-CoCoA (lane 6) for GST pull-down assays. Bound proteins were eluted with SDS sample buffer and analyzed by immunoblot with antibodies against GST (middle panel), or GST-β-catenin antibody (bottom panel), or anti-HA antibody (top panel). C, co-immunoprecipitation was performed as in B, using anti-CoCoA antisera for immunoprecipitation and anti-HA antibody (top panel) or anti-V5 antibody (lower panel) for immunoblots.

CoCoA and β-Catenin Synergistically Enhance Transcriptional Activation by AR and LEF1—A, CV-1 cells were transfected in 12-well plates with MMTV-LUC reporter plasmid (200 ng), pSV40-AR (50 ng), pSG5-HA-CoCoA (200 ng), and pSG5-HA-β-catenin (200 ng) as indicated, and grown in medium containing 20 nM dihydrotestosterone. Cell extracts were assayed for luciferase activity. B, CV-1 cells were transfected with pGL3OT reporter plasmid (200 ng), pSG5-HA-LEF1 (10 ng), pSG5-HA-β-catenin (200 ng), and pSG5-HA-CoCoA (200 or 400 ng) as indicated. Results shown are from a single experiment and representative of three independent experiments.
β-catenin and CoCoA (data not shown). Overexpression of CoCoA alone enhanced LEF1-mediated transcriptional activation of the wild-type LEF1 reporter gene pGL3OT, presumably due to cooperation with endogenous β-catenin. However, the dramatic coactivator synergy between exogenously expressed CoCoA and β-catenin (Fig. 2B, assays 5 and 6) coupled with the failure of CoCoA to bind LEF1 in GST pull-down assays (data not shown), suggest that CoCoA functions as a secondary coactivator for AR and TCF/LEF-mediated transcriptional activation; i.e. CoCoA is apparently recruited to the promoter through its interaction with the primary coactivator β-catenin not through a direct association with DNA-bound LEF1.

CoCoA Is Specifically Targeted to Transient and Endogenous TCF/LEF-responsive Enhancer Elements—Reporter Co-immunoprecipitation assays were used to test whether CoCoA is specifically recruited to TCF/LEF-responsive enhancer elements in vivo. COS-7 cells were transiently transfected with reporter plasmid pGL3OT along with plasmids encoding LEF1, β-catenin, and CoCoA, pGL3-SV40, which contains the same vector backbone as pGL3OT but lacks LEF1 binding sites, was also included as an internal control. Chromatin preparations from the transfected cells were immunoprecipitated with antibodies against LEF1, β-catenin, or CoCoA and protein A/G-Sepharose beads. The precipitated DNA was analyzed by PCR with primers recognizing the same backbone sequences in pGL3OT and pGL3-SV40; these primers produce amplification products of 318 bp from the pGL3OT plasmid and 412 bp from the pGL3-SV40 plasmid (Fig. 3A). PCR products amplified from the chromatin preparation before immunoprecipitation shows that the transfected COS-7 cells contain similar amounts of pGL3OT and pGL3-SV40 plasmids (Fig. 3A, lane 1). In the PCR products generated from DNA precipitated by antibodies against LEF1 (lane 2), β-catenin (lane 3), and CoCoA (lane 4), the 318-bp product was enriched relative to the 412-bp product, indicating that LEF1, β-catenin, and CoCoA associated preferentially with the pGL3OT plasmid containing the TCF/LEF-responsive elements. Beads with no antibody did not precipitate the plasmids (lane 5).

To test whether CoCoA is specifically recruited to a verified endogenous target gene of TCF/LEF and β-catenin, we employed the colon adenocarcinoma cell line SW480. These cells contain elevated levels of wild-type β-catenin due to a mutation in the adenomatous polyposis coli protein, which regulates β-catenin degradation, and they therefore have elevated expression of cyclin D1 mRNA and protein. The critical role of LEF1 and β-catenin in the elevated expression of the cyclin D1 gene has been demonstrated in SW480 cells by overexpression of the cytoplasmic region of N-cadherin, which competes with LEF1 for binding to β-catenin (27); by expression of a dominant negative form of TCF-4E (28); and by use of siRNA against β-catenin (29). Chromatin immunoprecipitation assays on SW480 cells demonstrated that LEF1, β-catenin, and CoCoA associated specifically with both sets of TCF/LEF enhancer elements in the cyclin D1 promoter, but not with a region 3 kb upstream, which lacked TCF/LEF binding sites (Fig. 3B). These results demonstrated the specific recruitment of LEF1, β-catenin, and CoCoA to TCF/LEF-responsive elements in vivo, supporting the roles of β-catenin and CoCoA as coactivators, which are recruited to TCF/LEF-responsive elements through their interaction with LEF1.

Endogenous CoCoA Is Required for the Coactivator Function of and Transcriptional Activation by β-Catenin—To further test the role of CoCoA as a mediator of transcriptional activation by β-catenin, small interfering RNA (siRNA) targeting CoCoA was transfected into COS-7 cells. Transfection of siRNA targeting CoCoA, but not control siRNA with scrambled sequences or siRNA targeting β-catenin, specifically reduced the level of endogenous CoCoA mRNA; but the β-actin mRNA level was not affected (Fig. 4A, upper panels). Similarly, β-catenin mRNA level was reduced by siRNA against β-catenin but not by the two scrambled sequence siRNAs (middle panel). Activation of the transiently transfected, TCF/LEF-controlled pGL3OT luciferase reporter gene was reduced by 70% by siRNA targeting CoCoA and siRNA targeting β-catenin. In contrast, luciferase activity was not reduced by similar amounts of one of the control siRNAs and was reduced only 30% by the second control siRNA (Fig. 4A, lower panel).

To confirm the specificity of the siRNA, we used a plasmid expressing an siRNA-resistant mutant of CoCoA (CoCoA-R) to perform a rescue experiment on cells treated with the CoCoA-specific siRNA. The
Coactivator Synergy between β-catenin and CoCoA

CoCoA-R expression plasmid contains three silent point mutations in the portion of the coding region of CoCoA that is targeted by the CoCoA-specific siRNA. Immunoblots indicated that expression of CoCoA-R in transient transfections was not affected by the CoCoA-specific siRNA, whereas the expression of wild-type CoCoA was severely reduced (Fig. 4B, upper panels). In the rescue experiment, the CoCoA-specific siRNA reduced the ability of transiently expressed LEF1 and β-catenin to activate the pGL3OT reporter plasmid by 75% (Fig. 4B, lower panel, assay I). In the absence of the siRNA, CoCoA wild-type and CoCoA-R mutant expression plasmids increased the reporter gene activity 3- to 4-fold (Fig. 4B, assays 2 and 3, white bars). The CoCoA-specific siRNA reduced by 30% the reporter gene activity in the cells transfected with the wild-type CoCoA expression plasmid (assays 2 and 3, black bars). The enhanced rescue achieved by overexpression of CoCoA-R compared with wild-type CoCoA confirms that the reduction in the expression of the pGL3OT reporter gene caused by the CoCoA-specific siRNA was specifically due to the reduction of cellular CoCoA levels.

To test further the role of CoCoA in mediating transcriptional activation by β-catenin, we tested the effect of the CoCoA-specific siRNA on the transcriptional activation function of β-catenin fused to Gal4 DBD. Activation of a reporter plasmid containing Gal4 DBD-β-catenin (150 ng), and 20 pmol of either siRNA targeting CoCoA or siRNA with scrambled sequence as indicated. Luciferase activity was measured 48 h after transfection. Results shown are representative of four independent experiments. To investigate the role of endogenous CoCoA on the expression of a specific endogenous target gene that is activated by LEF1 and β-catenin, we tested the effect of CoCoA-directed siRNA on the expression of the cyclin D1 gene in SW480 cells. In six independent experiments siRNA against CoCoA caused a substantial reduction in the cyclin D1 mRNA level, compared with a control siRNA with a scrambled sequence (Fig. 4D shows results of one typical experiment, and supplementary Fig. S1 shows the results and statistical analysis of all six experiments). These effects are gene-specific, because the results are normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA levels and are the mean and standard deviation from four quantitative PCR reactions for a single transfection experiment, which is representative of six independent experiments. For the six independent experiments, comparing cells treated with siCoCoA versus scrambled-sequence siRNA, p = 0.004 for CoCoA mRNA and p = 0.01 for cyclin D1 mRNA. Supplementary Fig. S1 shows the results and statistical analysis of all six experiments. These results show that the correlation coefficient R² is 0.91 for the six experiments when the levels of CoCoA mRNA and Cyclin D1 mRNA are compared in the cells which were treated with siRNA against CoCoA; this indicates that the siRNA against CoCoA causes a proportional decrease in the levels of CoCoA mRNA and Cyclin D1 mRNA.

FIGURE 4. Requirement of endogenous CoCoA for β-catenin and LEF1 function. A, COS-7 cells were transfected in 12-well plates with pGL3OT reporter plasmid (200 ng), pSG5.HA-LEF1 (100 ng), and either siRNA targeting CoCoA (siCoCoA), siRNA with scrambled sequence, or siRNA targeting β-catenin (+ + + 40 pmol, + + 60 pmol). Cell lysates were collected 48 h after transfection and used for luciferase assays (lower panel), or for preparation of total RNA for RT-PCR analysis using primers for CoCoA or β-actin cDNA (upper panels). B, for immunoblots (upper panels), COS-7 cells were transfected in 12-well plates with 1 μg of either pSG5.HA-CoCoA or pSG5.HA-CoCoA-R and the indicated amount (picomoles) of siRNA targeting CoCoA. Expression of HA-CoCoA was analyzed with anti-HA antibodies, and endogenous β-catenin was detected with anti-β-catenin antibodies. For transient reporter plasmid assays, CV-1 cells were transfected in 12-well plates with or without siRNA targeting CoCoA (40 pmol) using Lipofectamine 2000. 48 h after siRNA transfection, cells were transfected using Targefect F1 with pGL3OT (200 ng), pSG5.HA-LEF1 (1 ng), pSG5.HA-β-catenin (10 ng), and either pSG5.HA-CoCoA or pSG5HSHA-CoCoA-R (200 ng) as indicated. Cell lysates were prepared 24 h after plasmid transfection for measurement of luciferase activity. Results shown are representative of two independent experiments. C, COS-7 cells were transfected in 12-well plates with GK1-LUC reporter plasmid (200 ng), plasmids encoding Gal4 DBD or Gal4DBD-β-catenin (150 ng), and 20 pmol of either siRNA targeting CoCoA or siRNA with scrambled sequence as indicated. Luciferase activity was measured 48 h after transfection. Results shown are representative of four independent experiments. D, SW480 cells were transfected with 60 pmol of either siRNA targeting CoCoA or siRNA with scrambled sequence as indicated. Total RNA was collected and cDNA was produced for quantitative real-time PCR analysis. Results shown are normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA levels and are the mean and standard deviation from four quantitative PCR reactions for a single transfection experiment, which is representative of six independent experiments. For the six independent experiments, comparing cells treated with siCoCoA versus scrambled-sequence siRNA, p = 0.004 for CoCoA mRNA and p = 0.01 for Cyclin D1 mRNA. Supplementary Fig. S1 shows the results and statistical analysis of all six experiments. In addition supplementary Fig. S1 shows that the correlation coefficient R² is 0.91 for the six experiments when the levels of CoCoA mRNA and Cyclin D1 mRNA are compared in the cells which were treated with siRNA against CoCoA; this indicates that the siRNA against CoCoA causes a proportional decrease in the levels of CoCoA mRNA and Cyclin D1 mRNA.
Coactivator Synergy between β-Catenin and CoCoA

FIGURE 5. Domain requirements for β-catenin and CoCoA interaction. A, GST pull-down assays were performed as in Fig. 1, using COS-7 cell extracts containing HA-tagged CoCoA (full-length or fragments) and GST or GST-β-catenin bound to beads. The bound proteins were analyzed by immunoblot with anti-HA antibody. B, GST pull-down assays were performed as in Fig. 1, using COS-7 cell extracts containing HA-tagged β-catenin (full-length or fragments) and GST or GST-CoCoA bound to beads. The bound proteins were analyzed by immunoblot with anti-HA antibody.

dehyde-3-phosphate dehydrogenase mRNA levels. Thus, although several other coactivators (CBP/p300, CARM1, and GRIP1) are known to act along with CoCoA as downstream mediators of β-catenin in transcriptional activation (9, 22–26), simply reducing endogenous CoCoA levels causes a substantial decrease in the coactivator function of endogenous β-catenin on the endogenous cyclin D1 gene.

Interacting Domains of β-Catenin and CoCoA—To transmit the activating signal from the enhancer element-bound transcriptional activator protein to the transcription machinery, coactivators must have one or more signal input domains that interact with upstream components of the signaling pathway and one or more signal output domains that interact with downstream components of the pathway (16). Because CoCoA is downstream from β-catenin in the TCF/LEF transcriptional activation signaling pathway, we defined the one or more signal input domains of CoCoA that interact with β-catenin. GST-β-catenin was incubated with CoCoA fragments overexpressed in COS-7 cells. Surprisingly, the central coiled-coil region of CoCoA (amino acids 150–500), which is important for binding to p160 coactivators (21), was neither necessary nor sufficient for binding to β-catenin (Fig. 5A). Instead, both the N-terminal (amino acids 1–190) and C-terminal (amino acids 501–691) regions of CoCoA were capable of binding to β-catenin. Thus, CoCoA has two independent β-catenin binding sites.

To define the one or more regions of β-catenin that bind CoCoA, GST-CoCoA was incubated with β-catenin fragments overexpressed in COS-7 cells. In addition to full-length β-catenin, CoCoA bound to β-catenin fragments consisting of the 12 armadillo repeats or the last 3 armadillo repeats still attached to the C-terminal region of β-catenin (Fig. 5B). This indicates that armadillo repeats 10–12 of β-catenin are important for binding CoCoA. However, because a fragment consisting only of armadillo repeats 10–12 failed to bind CoCoA (data not shown), adjacent N-terminal or C-terminal regions flanking armadillo repeats 10–12 are also required. It is interesting to note that β-catenin (1–664), which contains all 12 armadillo repeats, but lacks the C terminus, failed to bind CoCoA, whereas full-length β-catenin and a fragment consisting only of the 12 repeats did bind. This suggests that the N-terminal region of β-catenin may have a negative-regulatory effect on the interaction, whereas the presence of the C-terminal region overcomes this negative regulation.

Different Domains of CoCoA Are Required to Mediate Transcriptional Activation by β-Catenin versus GRIP1—When CoCoA cooperates synergistically with the p160 coactivator GRIP1 to enhance ER-mediated transcriptional activation, the central coiled-coil domain of CoCoA is required for binding to GRIP1, and the C-terminal activation domain of CoCoA is needed as a signal output domain (21). As shown above (Fig. 5), different domains of CoCoA are required for binding to β-catenin than to GRIP1. Therefore, we also tested whether different domains of CoCoA are required for its coactivator function in cooperation with β-catenin and GRIP1. When CoCoA cooperates with β-catenin to enhance Lef1-mediated transcriptional activation, full-length CoCoA, and a mutant lacking the C-terminal end were effective coactivators, but a mutant lacking the N-terminal end was inactive (Fig. 6A). These mutant forms of CoCoA were expressed at levels similar to those of wild-type CoCoA (Fig. 5). In contrast to our findings for CoCoA domain requirements with β-catenin, the C-terminal region of CoCoA is required for its cooperation with GRIP1 to enhance ER-mediated transcriptional activation (21). Thus, the C-terminal region, but not the N-terminal region of CoCoA is required for its coactivator function with GRIP1 (21) (and data not shown), whereas the N-terminal but not the C-terminal region of CoCoA is needed for cooperation with β-catenin (Fig. 6A).

To test domain requirements of the coactivator function of CoCoA in a different setting, we used a mammalian-one hybrid format. Full-length CoCoA enhanced the ability of both Gal4DBD-β-catenin and Gal4DBD fused to the GRIP1 N-terminal domain (amino acids 5–479, the region that binds CoCoA) to activate transcription of a reporter gene containing Gal4 response elements (Fig. 6B, assays 1–3 and 6–8). In contrast, a CoCoA mutant lacking the C terminus strongly enhanced the activity of Gal4DBD-β-catenin, but had little or no effect on the activity of Gal4DBD-GRIP1N (Fig. 6B, assays 4–5 and 9–10). These results confirm the importance of the C-terminal region of CoCoA for mediating transcriptional activation by GRIP1 but not by β-catenin.

A third test format provided additional support for this conclusion. Reporter gene activation by Gal4DBD-CoCoA lacking the CoCoA C-terminal region was enhanced more strongly by β-catenin than by GRIP1 (Fig. 6C, assays 3). In contrast, Gal4DBD-CoCoA lacking the N-terminal region of CoCoA was more active with GRIP1 than with β-catenin (assays 4). Thus, although CoCoA can function as a secondary coactivator through either β-catenin or GRIP1, the specific domains required for its cooperation with each of these primary coactivators are different.

DISCUSSION

CoCoA Functions as a Secondary Coactivator for LEF1—The Wnt/β-catenin signaling pathway plays important roles in developmental processes such as cell fate determination and axis formation (30). The pathway regulates expression of target genes such as cyclin D1, c-myc, and BMP4 (2). Misregulation of this pathway leads to developmental defects and formation or progression of certain cancers. For example, β-catenin homozygous knock-out mice are embryonic lethal (31). In addition, mice with a transgene expressing a constitutively active form of β-catenin developed intestinal adenomas (32, 33). Approximately 90% of colorectal cancers and a smaller fraction of hepatocellular carcinomas were shown to have activating mutations in this pathway (2). Thus, it is
important to understand the molecular basis for regulation of this pathway.

Because CoCoA does not directly interact with LEF1 (data not shown), and because the coactivator function of CoCoA depends strongly on β-catenin (Fig. 2B), CoCoA is a secondary coactivator for LEF1. The role of CoCoA as a coactivator for TCF/LEF transcriptional activator proteins is further supported by our finding that CoCoA, along with LEF-1 and β-catenin, is specifically recruited to transiently transfected and endogenous promoters which are activated by LEF1 (Fig. 3).

The identification of armadillo repeats 10–12 as the CoCoA binding site (Fig. 5B) defines this region of β-catenin as a signal output domain of β-catenin. It is interesting to note that both the N-terminal region of β-catenin and the region from armadillo repeat 10 to the C terminus can bind to CBP and p300 (25, 26). It is not clear whether the C-terminal region of β-catenin can bind to both CBP/p300 and CoCoA at the same time or uses them as alternative or sequential downstream targets. The regions of β-catenin, which bind to CARM1 and GRIP1, have not been determined.

The physiological relevance of p300 and CBP as downstream targets for β-catenin was demonstrated by reducing their cellular level or inhibiting their activity with adenosovial protein EIA (25, 26). Here, the physiological relevance of CoCoA for mediating the action of LEF-1 and β-catenin on transiently transfected and endogenous target genes was demonstrated by reducing the endogenous levels of CoCoA with siRNA and by subsequently rescuing LEF-1 and β-catenin activity from the siRNA effect with an siRNA-resistant mutant of CoCoA (Fig. 4). In addition, endogenous CoCoA was specifically associated with the TCF/LEF enhancer elements of the endogenous cyclin D1 promoter in SW480 cells (Fig. 3B). In contrast, the roles of GRIP1 and CARM1 as secondary coactivators for LEF1 and β-catenin were primarily demonstrated through their abilities to bind to β-catenin and stimulate transcriptional activation by β-catenin and LEF1 in transient reporter gene assays (9, 22, 23).

**Differential Domain Requirements for CoCoA as a Coactivator—Coactivators constitute a multibranched signal transduction pathway that emanates from the DNA-bound transcriptional activator protein and results in the recruitment or activation of multiple target proteins that are components of the chromatin and transcription machinery. Each subunit of the coactivator signaling pathway presumably serves as a conduit for one branch of the signal and thus must have signal input domains, which bind to one or more upstream components of the pathway, and signal output domains, which interact with downstream components (16).**

Here we show that different regions of CoCoA are used as signal input and output domains when CoCoA cooperates with β-catenin than when it acts with GRIP1. When GRIP1 and CoCoA cooperate as primary and secondary coactivators, respectively (Fig. 7B), the central coiled-coil region of CoCoA acts as the signal input domain, which binds to and receives the activating signal from GRIP1 (21). The C-terminal activation domain of CoCoA is essential for its coactivator function and apparently serves as a signal output domain, transmitting the activating signal to an unknown downstream component (21).

In contrast, when β-catenin and CoCoA cooperate as primary and secondary coactivators, respectively (Fig. 7A), the N-terminal and C-terminal regions of CoCoA can bind to β-catenin and thus represent two potential signal input domains (Fig. 5A). The C-terminal region of CoCoA, which is essential for its coactivator function with GRIP1, is dispensable for the coactivator function of CoCoA with β-catenin (Fig. 6A). The fact that the CoCoA mutant lacking the C terminus still cooperates with β-catenin as a coactivator validates the N-terminal domain as a signal input domain. In addition, this finding indicates that the C terminus of CoCoA is not required as a signal output domain when
Coactivator Synergy between β-Catenin and CoCoA

FIGURE 7. Differential use of domains by CoCoA with β-catenin and GRIP1. A, when CoCoA serves as a secondary coactivator for β-catenin, the N-terminal and C-terminal regions of CoCoA (N and C in the diagram) bind to β-catenin and serve as signal input domains. The N-terminal domain may also serve as a signal output domain to transmit the activating signal (thick arrow) to an unknown target (possibly p300/CBP, which bind to this domain) in the transcription machinery, but the C-terminal domain is dispensable. Other coactivators, such as GRIP1, CARM1, and p300/CBP, can also participate in this complex. B, when CoCoA serves as a secondary coactivator for GRIP1, the coiled-coil domain of CoCoA binds to GRIP1 and serves as a signal output domain. The C-terminal activation domain serves as a signal output domain, transmitting the signal to an unknown downstream target. Other coactivators, such as CARM1 and p300/CBP, can also participate in this complex. RE, response element or enhancer element; TF, DNA-binding transcription factor; C-C, coiled-coil domain; Pol II complex; RNA polymerase II plus basal transcription factors; TATA, TATA box in the basal promoter; arrow emanating from the pol II complex, transcription start site and direction.

CoCoA cooperates with β-catenin; instead, the ability of the C-terminal domain to bind β-catenin suggests that it may serve as a redundant signal input domain. The CoCoA domain that serves as a signal output domain when CoCoA binds to β-catenin remains to be determined. However, our preliminary data indicate that the N-terminal region of CoCoA can bind p300,5 which suggests that the N-terminal region may provide both signal input and output functions when CoCoA collaborates with β-catenin.

Thus, CoCoA utilizes different signal input and output domains in response to activation signals sent from different primary coactivators (Fig. 7). Similar conclusions have been made for other coactivators. For example GRIP1 uses its LXXLL motifs to bind NRs (12) but uses its N-terminal basic helix-loop-helix-Per-Arnt-Sim (PAS) domain to bind to other classes of DNA-binding transcriptional activators, such as MEF-2C (35). In addition, GRIP1 uses one set of signal output domains when it acts as a coactivator for steroid hormone-dependent transcriptional activation on some promoters (36) and uses a different set of signal output domains when it functions as a corepressor for steroid hormone-dependent repression on other promoters (37).

Implication of CoCoA as a General Transcription Coactivator in Multiple Pathways—The fact that CoCoA, GRIP1, CARM1, p300/CBP, and β-catenin can form heterodimers in a variety of combinations suggests the possibility that they could form a multisubunit coactivator complex that associates with AR or LEF-1 on their target gene promoters. However, the potential activity of this group or complex of coactivators is not limited to the NR and TCF/LEF classes of transcriptional activators. Each of these five coactivators is known to bind directly to one or more DNA-binding transcriptional activator proteins. GRIP1 binds to NRs, AP-1, NFκB, HNF-1, MEF-2C, TEF4, and the aryl hydrocarbon receptor, among others (12, 35, 38–42). CBP and p300 interact with a huge variety of transcriptional activators (43). CARM1 binds to p53 and MEF-2C (44, 45). β-Catenin can bind to AR and LEF1 (4, 5, 8). CoCoA binds directly to the aryl hydrocarbon receptor and ARNT, which serves as a DNA-binding heterodimeric partner for the aryl hydrocarbon receptor and a number of other transcriptional activators (46). Thus, complexes composed of these five coactivators or subsets of them could potentially mediate transcriptional activation for an enormous variety of DNA-binding transcriptional activator proteins. Obviously, different subunits would serve as primary and secondary coactivators in different situations, and as shown here for CoCoA, different domains of each coactivator subunit will presumably serve as signal input and output domains in different situations.

If the same cofactor is used for mediating transcriptional regulation in multiple coactivator complexes or by multiple DNA-binding transcription factors, and if the cofactor is present in limiting amounts, then there will be competition for this limiting cofactor among the various transcriptional regulators that require its function. In essence, this means that, when one of the competing transcriptional regulators is activated, it will sequester the limiting cofactor and thus have a negative impact on signaling by the other transcriptional regulators that use the same limiting cofactor (47). For example, p300 and CBP serve as coactivators for many different DNA-binding transcriptional activator proteins, and limiting amounts of p300 and CBP have been proposed as a possible explanation for mutual antagonistic effects between different transcriptional activators that require these coactivators (48). Similarly, the antagonistic effect of the ligand-activated aryl hydrocarbon receptor on transcriptional activation by AR (49, 50) and the mutually antagonistic effects of activated AR and TCF/LEF on each other (9, 51, 52) might be due to competition for limiting cofactors, such as CoCoA, which are involved in transcriptional activation of both members of these antagonistic pairs of transcription factors. Thus, the involvement of CoCoA, β-catenin, GRIP1, and CARM1 in multiple transcriptional regulatory pathways (e.g. the Wnt/TCF and AR pathways discussed here) also makes them candidates for competitive regulation among these different pathways.

Acknowledgments—We thank Daniel Gerke (University of Southern California) for expert technical assistance and Dr. Susan Groshen and the Biostatistics Core of the University of Southern California/Norris Cancer Center for assistance with statistical analyses.

REFERENCES

1. Morin, P. J. (1999) BioEssays 21, 1021–1030
2. Giles, R. H., van Ex, J. H., and Clevers, H. (2003) Biochim. Biophys. Acta 1653, 1–24
3. Barker, N., and Clevers, H. (2000) BioEssays 22, 961–965
4. Billin, A. N., Thirwell, H., and Ayer, D. E. (2000) Mol. Cell Biol. 20, 6882–6890
5. Liu, T., DeCostanzo, A. J., Liu, X., Wang, H., Hallagan, S., Moon, R. T., and Malbon, C. C. (2001) Science 292, 1718–1722
6. Cavallo, R. A., Cox, R. T., Molina, M. M., Roose, J., Polevoy, G. A., Clevers, H., Peifer, M., and Bejsovec, A. (1998) Nature 395, 604–608
7. Brannon, M., Brown, J. D., Bates, R., Kimelman, D., and Moon, R. T. (1999) Development 126, 3159–3170
8. Truica, C. I., Byers, S., and Gelmann, E. P. (2000) Cancer Res. 60, 4709–4713
9. Song, L. N., Herrell, R., Byers, S., Shah, S., Wilson, E. M., and Gelmann, E. P. (2003) Curr. Biol. 13, 1763–1768
10. Song, L. N., Herrell, R., Byers, S., Shah, S., Wilson, E. M., and Gelmann, E. P. (2003) Nature 426, 228–234

5. C. K. Yang, J. H. Kim, H. Li, and M. R. Stallcup, unpublished data.
Coactivator Synergy between β-Catenin and CoCoA

33. Romenagolo, B., Berrebi, D., Saadi-Keddoussi, S., Porteu, A., Pichard, A. L., Peuch-maur, M., Vandewalle, A., Kahn, A., and Perret, C. (1999) Cancer Res. 59, 3875–3879
34. Barker, N., Hurlstone, A., Musisi, H., Miles, A., Bienz, M., and Clevers, H. (2001) EMBO J. 20, 4935–4943
35. Chen, S. L., Dowhan, D. H., Hosking, B. M., and Muscat, G. E. (2000) Genes Dev. 14, 1209–1228
36. Ma, H., Hong, H., Huang, S.-M., Irvine, R. A., Webb, P., Kushner, P. J., Coetzee, G. A., and Stallcup, M. R. (1999) Mol. Cell Biol. 19, 6164–6173
37. Rogatsky, I., Luecke, H. F., Leitman, D. C., and Yamamoto, K. R. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 16701–16706
38. Lee, S. K., Kim, H. J., Na, S. Y., Kim, T. S., Choi, H. S., Im, S. Y., and Lee, J. W. (1998) J. Biol. Chem. 273, 16651–16654
39. Sheppard, K. A., Rose, D. W., Haque, Z. K., Kurokawa, R., McInerney, E., Westin, S., Thanos, D., Rosenfeld, M. G., Glass, C. K., and Collins, T. (1999) Mol. Cell Biol. 19, 6367–6378
40. Soutoglou, E., Papafotiou, G., Katrakili, N., and Talianidis, I. (2000) J. Biol. Chem. 275, 12515–12520
41. Belandia, B., and Parker, M. G. (2000) J. Biol. Chem. 275, 30801–30805
42. Beischlag, T. V., Wang, S., Rose, D. W., Torchia, J., Reisz-Porszasz, S., Muhammad, K., Nelson, W. E., Probst, M. R., Rosenfeld, M. G., and Hankinson, O. (2002) Mol. Cell Biol. 22, 4319–4333
43. Vo, N., and Goodman, R. H. (2001) J. Biol. Chem. 276, 13505–13508
44. An, W., Kim, J., and Roeder, R. G. (2004) Cell 117, 735–748
45. Chen, S. L., Loeffler, K. A., Chen, D., Stallcup, M. R., and Muscat, G. E. (2002) J. Biol. Chem. 277, 4324–4333
46. Kim, J. H., and Stallcup, M. R. (2004) J. Biol. Chem. 279, 49842–49848
47. Meyer, M. E., Gronemeyer, H., Turcotte, B., Riscucl, M. T., Tasset, D., and Chambon, P. (1989) Cell 57, 433–442
48. Kamei, Y., Xiao, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) Cell 85, 403–414
49. Kurz, R., Okamura, K., Toriba, A., Kakishima, H., Mizokami, A., Burnstein, K. L., and Hayakawa, K. (2003) J. Biol. Chem. 278, 335–343
50. Morrow, D., Qin, C., Smith, R., and Safe, S. (2004) J. Steroid Biochem. Mol. Biol. 88, 27–36
51. Mulholland, D. J., Read, J. T., Rennie, P. S., Cox, M. E., and Nelson, C. C. (2003) Oncogene 22, 5602–5613
52. Chesire, D. R., and Isaacs, W. B. (2002) Oncogene 21, 8453–8469